


Study: Paxlovid reduces risk of long-term health problems, death from COVID-19


March 24 2023, by Kristina Sauerwein

A PCC




No. at risk		246076	235468	225891	216902	205222	189205
No treatment		246076	235468	225891	216902	205222	189205
Nirmatrelvir		35717	31549	28461	25920	22898	18134
Cumulative No. of events							
No treatment		0	13313	21638	27610	32354	36572
Nirmatrelvir		0	1075	1837	2452	3060	3526

B Death




No. at risk		246076	235468	225891	216902	205222	189205
No treatment		246076	235468	225891	216902	205222	189205
Nirmatrelvir		35717	31549	28461	25920	22898	18134
Cumulative No. of events							
No treatment		0	1421	2263	3004	3608	4101
Nirmatrelvir		0	54	98	141	184	207

C Hospitalization



No. at risk		246076	230614	218357	207516	194640	178148
No treatment		246076	230614	218357	207516	194640	178148
Nirmatrelvir		35717	31080	27706	24976	21831	17102
Cumulative No. of events							
No treatment		0	5311	8493	10966	12989	14617
Nirmatrelvir		0	530	888	1174	1450	1655

D Death or hospitalization



No. at risk		246076	230614	218357	207516	194640	178148
No treatment		246076	230614	218357	207516	194640	178148
Nirmatrelvir		35717	31080	27706	24976	21831	17102
Cumulative No. of events							
No treatment		0	6577	10388	13375	15817	17739
Nirmatrelvir		0	573	961	1276	1575	1794

Event Rates of Post–Acute Outcomes in Nirmatrelvir and No-Treatment Control Group A, Post–COVID-19 condition (PCC). B, Death. C, Hospitalization. D, Composite outcome of death or hospitalization. Outcomes were ascertained 30 days after the SARS-CoV-2 positive test until the end of follow-up. Event rates in percentage presented for the nirmatrelvir group (blue, n = 35 717) and the

control group (orange, n = 246 076). Shaded areas are 95% CIs. Credit: *JAMA Internal Medicine* (2023). DOI: 10.1001/jamainternmed.2023.0743

The risk of long-term health problems, hospitalization and death after a COVID-19 infection diminishes among those who take the antiviral drug Paxlovid within five days after testing positive, according to an analysis of federal health data by researchers at Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care system.

Paxlovid works to stop the virus that causes COVID-19 from multiplying, and reduces the amount of virus in the body. The medication's benefits last up to six months after infection, the study showed. Further, the effects extend to those who are unvaccinated, vaccinated, and vaccinated with subsequent booster shots, as well as to people who have recovered from COVID-19 but later are reinfected one or more times.

The findings were published March 23 in *JAMA Internal Medicine*.

Paxlovid, developed by Pfizer, is the brand name for an oral antiviral medication that contains the drugs nirmatrelvir and ritonavir. In late 2021, the U.S. Food and Drug Administration issued an emergency use authorization allowing for the medication to be prescribed to treat mild to moderate COVID-19 in people at risk of progression to severe COVID-19. Those considered at risk are people age 50 or older; and adults or children age 12 or older who have heart, kidney and lung diseases; diabetes or obesity; or cancer or immune disorders, among other conditions.

"Long COVID-19 has become an urgent public health problem that

poses wide-ranging concerns—from decreased life expectancy rates, to burdened health-care and employment systems, to weakened economies on local levels, in the U.S. and abroad," said senior author Ziyad Al-Aly, MD, a Washington University clinical epidemiologist who has studied extensively the long-term effects of COVID-19 infection. "Our study suggests Paxlovid is an effective weapon against COVID-19's potential for debilitating and life-threatening effects on the body."

The World Health Organization has tracked about 760 million cases of COVID-19 since the pandemic began three years ago. It estimates that one in five of those infected—or roughly 152 million people—have suffered from long COVID-19, a condition linked to [heart attack](#), stroke, memory disorders, debilitating fatigue, pancreatitis, liver malfunction, epileptic seizures, chronic kidney disease, diabetes, depression and death.

Other complications associated with long COVID-19 include [irritable bowel syndrome](#), acid reflux, ulcers, hearing and vision abnormalities, migraine headaches, blood clots, and brain inflammation. Since the pandemic's beginning in 2019, Al-Aly and his research team have studied about 80 adverse health outcomes associated with long COVID-19.

For the latest study, researchers analyzed de-identified prescription records of 281,793 people with SARS-CoV-2 infection who had at least one risk factor for progression to severe COVID-19 illness. They examined records from Jan. 3, 2022, through Dec. 31, 2022, from a database maintained by the U.S. Department of Veterans Affairs, the nation's largest integrated health care system.

They created controlled [data sets](#) of 246,076 people who had not been prescribed Paxlovid (or other drugs) and 35,717 who had received Paxlovid within five days of testing positive for COVID-19. Patients

were mostly older, [white males](#); however, the researchers used statistical modeling for parity comparisons.

The analysis showed that Paxlovid reduced the risk of long COVID-19 by 26% over a six-month period. Similarly, during the same time span, Paxlovid decreased the risk of death by 47% and the risk of hospitalization by 24%.

"All hypotheses of long COVID point to SARS-CoV-2 as the initiating agent," Al-Aly said. "Our research reinforces such theories. It stands to reason that an antiviral drug—one that suppresses viral replication—may reduce the risk of long COVID.

"This gives me hope that antivirals may hold the key to preventing long COVID-19," he added. "More research is needed to determine whether antiviral drugs other than Paxlovid are also effective at preventing long COVID."

More information: Yan Xie et al, Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition, *JAMA Internal Medicine* (2023). [DOI: 10.1001/jamainternmed.2023.0743](https://doi.org/10.1001/jamainternmed.2023.0743)

Provided by Washington University School of Medicine in St. Louis

Citation: Study: Paxlovid reduces risk of long-term health problems, death from COVID-19 (2023, March 24) retrieved 27 April 2024 from <https://medicalxpress.com/news/2023-03-paxlovid-long-term-health-problems-death.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.